

Studien der Arbeitsgruppe Senologie

Mit der Durchführung betraute Mitarbeiter	Name der Studie	Firma/ Sponsor/ Organisation	Studiendauer	AZ der inkl. Pat per 31.12.2012
Gschwantler-Kaulich D* , Nemeč A	ABCSG Studie 8	ABCSG	Bis 2019	119
Gschwantler D*, Nemeč A	ABCSG Studie 12	ABCSG	Bis 30.11.2014	55
Singer C, Nemeč A	ABCSG Studie 15 BIG 05-02	ABCSG	Bis 12/2018	4
Singer C, Gschwantler-Kaulich D*, Nemeč A	ABCSG Studie 16 - SALSA	ABCSG	Bis 12/2019	94
Singer C, Fink-Retter*, Gschwantler-Kaulich D*, Brandl I	ABCSG 18 - A randomized, double-blind, placebo-controlled, multi-center phase 3 study to determine the treatment effect of denosumab in subjects with non-metastatic breast, breast cancer receiving aromatase inhibitor therapy	ABCSG	01.12.2006-30.04.2012	286
Galid A	ABCSG 19 - Hera B016348 Herceptin	ABCSG	Bis 08/2014	11
Singer C, Fink-Retter A*, Gschwantler-Kaulich D*, Brandl I	ABCSG 23 - Randomisierte multizentrische offene Phase IIIb-Studie von Letrozol gegen anastrozol in der adjuvanten Therapie postmenopausaler Frauen mit Hormonrezeptor- und Lymphknoten-positivem Brustkrebs (CFEM345D2411)	ABCSG	01.08.2006-31.07.2012	8
Singer C, Fink-Retter A*, Brandl I	ABCSG 25 Study - Comparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel versus three weekly epirubicin + cyclophosphamide, 5-fluorouracil followed by docetaxel (FEC) in lymph node positive breast cancer patients - a continuation of the feasibility part of the SBG 2004-1 study	ABCSG	01.12.2007-30.11.2010	55
Singer C, Muin D, Brandl I	ABCSG 26 – A phase III trial evaluating the role of continuous letrozole vs intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer - SOLE	ABCSG	01.01.2011-31.12.2015	8
Singer C, Pfeiler G, Tea M, Brandl I	ABCSG 28 Positive – primary operation in synchronous metastasized invasive breast cancer, a multicenter prospective randomized study to evaluate the use of local therapy	ABCSG	01.09.2010-31.08.2014	1
Singer C, Fink-Retter A*, Brandl I	ABCSG 27 - Internationale multizentrische, zweiarmige open-label-Phase III Studie zur adjuvanten Therapie mit Bevacizumab beim dreifach negativem (triple-negative) Mammakarzinom / BEATRICE /	ABCSG / Quinteles / Hofmann La Roche	01.11.2007-31.06.2019	11
Singer C, Brandl I	A multicentre phase III randomized Study of adjuvant therapy for patients with HER-2-positive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab BETH - ABCSG 30	ABCSG	01.11.2008-31.05.2021	4
Singer C, Tea M, Brandl I	ABCSG 32 - Multicentre randomized phase II study for operable mammary carcinoma with neoadjuvant Trastuzumab plus Docetaxel with and without Bevacizumab and Trastuzumab plus Docetaxel plus non-pegylated liposome-encapsulated Doxorubicin (NPLD) with and without bevacizumab in HER2-positive early breast cancer – ML22765	ABCSG	01.04.2011-30.09.2013	4

Singer C, Staudigl C, Brandl I	ABCSG 34 – A prospective open, randomized, phase- II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax) in the pre-operative treatment of women with primary breast cancer	ABCSG	01.03.2012- 28.02.2014	16
Singer C, Tea M, Brandl I	ABCSG 39 – A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer	ABCSG	01.05.2012- 31.12.2025	5
Singer C, Fink-Retter A*, Brandl I	A randomized, 4-arm, placebo-controlled phase 2 trial of AMG 386 in combination with bevacizumab and paclitaxel or AMG 386 plus paclitaxel as first-line therapy in subjects with HER-2-negative, metastatic or locally recurrent breast cancer AMG2006-0341	Fa. Amgen	19.11.2007- 31.12.2015	1
Singer C, Fink-Retter A*, Nemec A, Gschwantler- Kaulich D*	An observational study of cardiac events in patients with HER-2positive early breast treated with herceptin OHERA / BO20652	Quinteles / Hofmann La Roche	01.12.2007- 31.10.2014	17
Singer C, Staudigl C	Prospektiv internationale Studie zur Beobachtung des Neutropenie und Anämiemanagements bei Patienten mit soliden Tumoren, die eine myelotoxische Chemotherapie erhalten (Studie Nr. 20060445)	Fa. Amgen	01.02.2008- 31.12.2014	38
Singer C, Brandl I	Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study EGF 106708 ALTT0:EGF 106708 ABCSG 31	ABCSG	01.04.2009- 31.03.2019	1
Singer C, Gschwantler-Kaulich D*, Brandl I	Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid	Pierre Fabre	01.10.2009- 31.03.2012	2
Singer C, Fink-Retter A*,	A phase III randomized study evaluating the efficacy and safety of continued and re-induced bevacizumab in combination with chemotherapy for patients with locally recurrent or metastatic breast cancer after first-line chemotherapy and bevacizumab treatment (TANIA) Proj.Nr. TANIA-RO4876646	Fa. Roche	01.01.2011- 31.12.2013	2
Singer C, Staudigl C	A prospective Dose Intensity and Neutropenia Prophylaxis Evaluation Program in patients receiving myelosuppressive chemotherapy of high risk of febrile neutropenia for different types DIEPP Proj.Nr.: AMG20100088	Fa. Amgen	01.02.2011- 30.06.2013	11
Singer C, Staudigl C	A prospective, randomized, multicenter study to evaluate the impact of Ferric(III)-Carboxymaltose in comparison to a combination of Darbopoetin alpha and Ferric(III)-Carboxymaltose and to Darbopoetin alpha alone in patients with chemotherapy-induced anemia	Fa. VIFOR	01.02.2011- 31.07.2013	0
Singer C, Tea M, Blümel E	A dose-escalating phase I study to evaluate the safety, pharmacokinetics and efficacy of PDC31 in patients with primary dysmenorrhea, Proj. Nr. PDC-3111	Fa. PDC Biotech	01.01.2011- 30.06.2012	2
Singer C, Brandl I, Blümel E	Belle 4 – A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with Her2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pathway activation	Fa. Novartis	01.06.2012- 31.03.2015	1
Singer C, Tea M, Winkler-Dobrovits E, Brandl I,	A multicenter, single arm study of trastuzumab emtansine (T-DM1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti-her2 and Chemotherapy-based treatment	Fa. Roche	01.10.2012- 30.06.2014	1

Blümel E				
Singer C, Zaafarani S, Blümel I	Serum-Autoantibody testing for early diagnostics of Breast Cancer Proj. Nr. LS11-026	WWTF	01.05.2012- 30.04.2015	50
Seifert M, Brandl I	ABRAXANE-MBC-1 – A non-interventional single arm observational study in subjects treated with nab-paclitaxel	Fa. Celgene	01.07.2012- 31.07.2014	5
Singer C, Fink-Retter A*, Brandl I	PERUSE - A multicenter, open-label, single arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2-positive advanced (metastatic or locally recurrent) breast cancer.	Fa. Roche	15.03.2012- 14.03.2019	0

* derzeit in Karenz